Rockport Wealth LLC Takes Position in Glaukos Corporation $GKOS

Key Points

• Rockport Wealth LLC acquired 11,497 shares of Glaukos Corporation (NYSE:GKOS), valued at approximately $1,132,000, during the first quarter.
• Analysts have set a consensus price target of $127.42 for Glaukos, with ratings ranging from "Strong Buy" to "Hold" from various research firms.
• Glaukos reported $124.12 million in revenue for the quarter, exceeding analysts' expectations, and posted an EPS of ($0.24), surpassing the consensus estimate.

Rockport Wealth LLC acquired a new stake in Glaukos Corporation (NYSE:GKOS - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 11,497 shares of the medical instruments supplier's stock, valued at approximately $1,132,000.

Other institutional investors also recently bought and sold shares of the company. Bessemer Group Inc. raised its position in Glaukos by 133.9% during the 1st quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock worth $27,000 after buying an additional 158 shares during the last quarter. Whipplewood Advisors LLC grew its stake in Glaukos by 3,957.1% in the 1st quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock valued at $28,000 after acquiring an additional 277 shares during the period. First Horizon Advisors Inc. grew its stake in Glaukos by 72.9% in the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock valued at $37,000 after acquiring an additional 159 shares during the period. Versant Capital Management Inc grew its stake in Glaukos by 583.9% in the 1st quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock valued at $38,000 after acquiring an additional 327 shares during the period. Finally, CoreCap Advisors LLC boosted its stake in Glaukos by 36.4% during the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock worth $112,000 after purchasing an additional 200 shares during the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

GKOS has been the topic of several recent research reports. UBS Group lifted their target price on shares of Glaukos from $125.00 to $134.00 and gave the stock a "buy" rating in a research note on Thursday, July 31st. William Blair upgraded shares of Glaukos to a "strong-buy" rating in a report on Thursday, July 31st. Zacks Research cut shares of Glaukos from a "strong-buy" rating to a "hold" rating in a report on Friday, August 15th. Mizuho set a $130.00 price objective on shares of Glaukos in a report on Thursday, July 31st. Finally, Wells Fargo & Company upped their target price on shares of Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $124.83.

Glaukos Stock Performance

Shares of Glaukos stock traded down $3.20 during trading hours on Wednesday, hitting $87.72. 866,980 shares of the company were exchanged, compared to its average volume of 636,688. Glaukos Corporation has a 1 year low of $77.10 and a 1 year high of $163.71. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09. The business has a 50-day moving average of $94.22 and a 200-day moving average of $96.34. The stock has a market capitalization of $5.03 billion, a price-to-earnings ratio of -53.16 and a beta of 0.77.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.02. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The business had revenue of $124.12 million during the quarter, compared to analysts' expectations of $115.49 million. During the same quarter in the prior year, the business earned ($0.52) earnings per share. The company's quarterly revenue was up 29.7% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. As a group, analysts expect that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.